samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > biotechnology and patents from the finnish point of view
PUBLICATIONS
European Biopharmaceutical Review

Biotechnology and Patents From the Finnish Point of View

During the 80s and 90s, there was a remarkable investment boom in Finland in the biotechnological sector, and this trend is still continuing. With more than 115 biotechnology companies, Finland can be ranked amongst the top European countries in terms of number of biotechnological firms.Biotechnology comprises a large sector. Approximately half the businesses operating in Finland concentrate on health products such as pharmaceuticals. In general terms, the use of biotechnology in the pharmaceutical industry is increasing. It is estimated that biotechnology has been used in every fifth new pharmaceutical brought onto the market.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

KKR Invests in Biosynth Carbosynth to Accelerate Growth and Help Build Global Life Sciences Tools Platform

London and Staad, 1 November 2021 KKR, a leading global investment firm, and Biosynth Carbosynth, a leading life sciences reagents and custom synthesis and manufacturing services company, announce today that KKR has agreed to acquire Biosynth Carbosynth from Armira and CEO Dr. Urs Spitz. Dr. Spitz and senior managers of the company will retain a significant ownership stake and will continue to lead the company as it embarks on its next chapter of growth. Financial details of the transaction, which is subject to customary regulatory approvals, were not disclosed.
More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement